Literature DB >> 15845781

Drug resistance and antiretroviral drug development.

Robert W Shafer1, Jonathan M Schapiro.   

Abstract

As more drugs for treating HIV have become available, drug resistance profiles within antiretroviral drug classes have become increasingly important for researchers developing new drugs and for clinicians integrating new drugs into their clinical practice. In vitro passage experiments and comprehensive phenotypic susceptibility testing are used for the pre-clinical evaluation of drug resistance. Clinical studies are required, however, to delineate the full spectrum of mutations responsible for resistance to a new drug and to identify the settings in which a new drug is likely to be most useful for salvage therapy.

Mesh:

Substances:

Year:  2005        PMID: 15845781      PMCID: PMC2547472          DOI: 10.1093/jac/dki127

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Timing the ancestor of the HIV-1 pandemic strains.

Authors:  B Korber; M Muldoon; J Theiler; F Gao; R Gupta; A Lapedes; B H Hahn; S Wolinsky; T Bhattacharya
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

2.  World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

Authors:  P R Harrigan; J S Montaner; S A Wegner; W Verbiest; V Miller; R Wood; B A Larder
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

3.  Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

Authors:  Dale J Kempf; Jeffrey D Isaacson; Martin S King; Scott C Brun; Jacquelyn Sylte; Bruce Richards; Barry Bernstein; Richard Rode; Eugene Sun
Journal:  Antivir Ther       Date:  2002-09

4.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.

Authors: 
Journal:  HIV Clin Trials       Date:  2000 Jul-Aug

5.  Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

Authors:  M J Gonzales; R N Machekano; R W Shafer
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

6.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Authors:  N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 8.  Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV.

Authors:  Neil T Parkin; Jonathan M Schapiro
Journal:  Antivir Ther       Date:  2004-02

9.  Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.

Authors:  E Randall Lanier; Mounir Ait-Khaled; Janna Scott; Chris Stone; Thomas Melby; Glenn Sturge; Marty St Clair; Helen Steel; Seth Hetherington; Gillian Pearce; William Spreen; Stephen Lafon
Journal:  Antivir Ther       Date:  2004-02

10.  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors:  M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal:  Antivir Ther       Date:  1999
View more
  6 in total

1.  A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance.

Authors:  Patricia Buendia; Brice Cadwallader; Victor DeGruttola
Journal:  Bioinformatics       Date:  2009-08-03       Impact factor: 6.937

2.  Drug-resistance mechanisms and tuberculosis drugs.

Authors:  Claudio U Köser; Babak Javid; Kathleen Liddell; Matthew J Ellington; Silke Feuerriegel; Stefan Niemann; Nicholas M Brown; William J Burman; Ibrahim Abubakar; Nazir A Ismail; David Moore; Sharon J Peacock; M Estée Török
Journal:  Lancet       Date:  2015-01-24       Impact factor: 79.321

3.  Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.

Authors:  Samir Abdurahman; Akos Végvári; Masoud Youssefi; Michael Levi; Stefan Höglund; Elin Andersson; Peter Horal; Bo Svennerholm; Jan Balzarini; Anders Vahlne
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

4.  Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Rebekah Barr; Vinay K Pathak
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

5.  Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.

Authors:  Pankhuri Arora; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2009-03-13       Impact factor: 4.475

6.  Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.

Authors:  Jonathan C Reed; Dennis Solas; Anatoliy Kitaygorodskyy; Beverly Freeman; Dylan T B Ressler; Daryl J Phuong; J Victor Swain; Kent Matlack; Clarence R Hurt; Vishwanath R Lingappa; Jaisri R Lingappa
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.